Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

AIMS: Contemporary adjuvant treatment for early breast cancer is associated with improved survival but at the cost of increased risk of cardiotoxicity and cardiac dysfunction. We tested the hypothesis that concomitant therapy with the angiotensin receptor blocker candesartan or the β-blocker metopro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulati, Geeta, Heck, Siri Lagethon, Ree, Anne Hansen, Hoffmann, Pavel, Schulz-Menger, Jeanette, Fagerland, Morten W., Gravdehaug, Berit, von Knobelsdorff-Brenkenhoff, Florian, Bratland, Åse, Storås, Tryggve H., Hagve, Tor-Arne, Røsjø, Helge, Steine, Kjetil, Geisler, Jürgen, Omland, Torbjørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Aha Fasttrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887703/
https://www.ncbi.nlm.nih.gov/pubmed/26903532
http://dx.doi.org/10.1093/eurheartj/ehw022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887703/
https://www.ncbi.nlm.nih.gov/pubmed/26903532
http://dx.doi.org/10.1093/eurheartj/ehw022

Ejemplares similares